Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19013912 | 0.79 | HPGD (0.45) | FFAR1KEAP1P4HTMPLA2G10PLA2G2A | |
| SCHEMBL12815057 | 0.79 | KDM4E (0.50) | GPR17FFAR1KEAP1 | |
| SCHEMBL2964327 | 0.79 | FFAR1 (0.46) | FFAR1TBXAS1 | |
| SCHEMBL29009956 | 0.79 | FFAR1 (0.46) | FFAR1KEAP1PLA2G10PLA2G2APLA2G5 | |
| SCHEMBL7768336 | 0.79 | RECQL (0.47) | FFAR1KEAP1P4HTMTBXAS1 | |
| SCHEMBL30405680 | 0.79 | NR4A2 (0.49) | GPR17FFAR1NR4A2 | |
| SCHEMBL31422477 | 0.76 | FFAR1 (0.40) | FFAR1KEAP1P4HTMTBXAS1 | |
| SCHEMBL2559602 | 0.76 | FFAR1 (0.43) | FFAR1KEAP1P4HTMPLA2G10PLA2G2A | |
| SCHEMBL18534149 | 0.76 | PLA2G10 (0.38) | FFAR1KEAP1P4HTMPLA2G10PLA2G2A | |
| SCHEMBL15160638 | 0.75 | HDAC8 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414036-B2 | Compounds useful as A3 adenosine receptor agonists | MUSCAGEN LIMITED (GB) | 2008-08-19 | — | — | US | disclosed |
| US-20050101551-A1 | Compounds useful as A3 adenosine receptor agonists | MUSCAGEN LIMITED (GB) | 2005-05-12 | — | — | US | disclosed |
| WO-2005012323-A2 | COMPOUNDS USEFUL AS A3 ADENOSINE RECEPTOR AGONISTS | TRIGEN LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-1469864-A1 | COMPOUNDS USEFUL AS A-3 ADENOSINE RECEPTOR AGONISTS | MUSCAGEN LIMITED (GB) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003061670-A1 | COMPOUNDS USEFUL AS A3 ADENOSINE RECEPTOR AGONISTS | MUSCAGEN LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101551-A1 | Compounds useful as A3 adenosine receptor agonists | ADORA3, ADORA2A, ADORA2B | GPR17 64/4885FFAR1 684/4885BCHE 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.